Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma-a prospective multicenter observational study pointing out new unmet needs.
作者信息
Damen Pim J J, Verhoeff Joost J C
机构信息
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
出版信息
Transl Cancer Res. 2023 Mar 31;12(3):688-691. doi: 10.21037/tcr-22-2841. Epub 2023 Feb 27.
Abstract
摘要
相似文献
1
Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma-a prospective multicenter observational study pointing out new unmet needs.
Transl Cancer Res. 2023 Mar 31;12(3):688-691. doi: 10.21037/tcr-22-2841. Epub 2023 Feb 27.
2
tereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC).
Clin Transl Radiat Oncol. 2022 Jan 5;33:115-119. doi: 10.1016/j.ctro.2021.12.008. eCollection 2022 Mar.
3
Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study.
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):655-665. doi: 10.1016/j.ijrobp.2022.05.013. Epub 2022 May 18.
4
Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors.
Anticancer Res. 2022 Oct;42(10):4795-4804. doi: 10.21873/anticanres.15984.
5
Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer.
Case Rep Oncol. 2016 Aug 17;9(2):474-480. doi: 10.1159/000448804. eCollection 2016 May-Aug.
6
Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Int J Mol Sci. 2019 May 2;20(9):2173. doi: 10.3390/ijms20092173.
7
PD-1 Restrains Radiotherapy-Induced Abscopal Effect.
Cancer Immunol Res. 2015 Jun;3(6):610-9. doi: 10.1158/2326-6066.CIR-14-0138. Epub 2015 Feb 19.
8
Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
Ann Palliat Med. 2021 May;10(5):5944-5953. doi: 10.21037/apm-20-1409. Epub 2021 Feb 23.
9
Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer.
Front Oncol. 2023 Jan 16;12:1092875. doi: 10.3389/fonc.2022.1092875. eCollection 2022.
10
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Lancet Oncol. 2019 Apr;20(4):494-503. doi: 10.1016/S1470-2045(18)30896-9. Epub 2019 Feb 12.
引用本文的文献
1
Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy.
Clin Cancer Res. 2024 Jun 3;30(11):2317-2332. doi: 10.1158/1078-0432.CCR-23-3632.
2
Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study.
BMJ Open. 2023 Nov 21;13(11):e076715. doi: 10.1136/bmjopen-2023-076715.
本文引用的文献
1
Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors.
Anticancer Res. 2022 Oct;42(10):4795-4804. doi: 10.21873/anticanres.15984.
2
Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study.
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):655-665. doi: 10.1016/j.ijrobp.2022.05.013. Epub 2022 May 18.
3
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13.
4
The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis.
Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):936-948. doi: 10.1016/j.ijrobp.2021.07.1695. Epub 2021 Jul 28.
5
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
Eur J Cancer. 2021 Jul;151:72-83. doi: 10.1016/j.ejca.2021.04.003. Epub 2021 May 7.
6
Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?
Cancers (Basel). 2021 Apr 28;13(9):2132. doi: 10.3390/cancers13092132.
7
Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.
Lung Cancer. 2021 Apr;154:36-43. doi: 10.1016/j.lungcan.2021.01.022. Epub 2021 Jan 27.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Lancet Respir Med. 2021 May;9(5):467-475. doi: 10.1016/S2213-2600(20)30391-X. Epub 2020 Oct 20.
10
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001001.
Zotero 插件